Early detection slows Parkinson progression
- Trial ID
- NCT07467460
- Official Title
- NEUROTECHNO: Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.
- Goal
- Early detection slows Parkinson progression
- Status
- RECRUITING
- Sponsor
- Neuromed IRCCS
- Study Type
- OBSERVATIONAL
- Enrollment
- 500 participants
- Conditions
- PARKINSON DISEASE (Disorder), Alzheimer s Disease, Diabete Type 2
Plain-Language Summary
Aiming to build precision medicine tools that improve diagnosis and personalize care for Parkinson's and Alzheimer's by linking clinical features with biological markers. The project is observational, collecting clinical exams, imaging and biomarkers like amyloid PET and cerebrospinal fluid measures, plus detailed medication-response data for Parkinson's, for example documented responses to L‑dopa, which is converted to dopamine to replace the brain's lost dopamine, and to dopamine agonists, so researchers can predict who will benefit from specific therapies. Recruiting about 500 adults 18 and older, it is looking for people with Parkinson's who have at least two cardinal signs including tremor or bradykinesia and no atypical features, or people with probable Alzheimer's confirmed by amyloid biomarkers; people with pre-existing psychiatric disorders, other neurodegenerative diseases, or dementia are excluded.
Locations
- IRCCS INM Neuromed, Pozzilli, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Aiming to build precision medicine tools that improve diagnosis and personalize care for Parkinson's and Alzheimer's by linking clinical features with biological markers. The project is observational, collecting clinical exams, imaging and biomarkers like amyloid PET and cerebrospinal fluid measures, plus detailed medication-response data for Parkinson's, for example documented responses to L‑dopa, which is converted to dopamine to replace the brain's lost dopamine, and to dopamine agonists, so researchers can predict who will benefit from specific therapies. Recruiting about 500 adults 18 and older, it is looking for people with Parkinson's who have at least two cardinal signs including tremor or bradykinesia and no atypical features, or people with probable Alzheimer's confirmed by amyloid biomarkers; people with pre-existing psychiatric disorders, other neurodegenerative diseases, or dementia are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 7 months.